Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma

使用曲美替尼和GSK2141795进行MEK/AKT双重抑制治疗，对转移性NRAS突变型和野生型黑色素瘤均无临床获益。